Prof. T. Kendall Harden

Ken Harden is a Kenan Distinguished Professor at the Department of Pharmacology at the University of North Carolina at Chapel Hill where his research interests focus on Phospholipase C and inositol lipid signaling, P2Y receptors for extracellular nucleotides and G proteins.

Dr. Wolgang Pieken

Wolfgang Pieken serves as fund manager at Inveni Capital and has held several executive management positions in biotech companies in Europe and the US. His last position was CEO of the German MWG Biotech AG. He currently serves as as Board members in various companies including Priaxon GmbH.